These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 140184)

  • 1. Suppression of immune complex-induced inflammation by the chemotactic factor inactivator.
    Johnson KJ; Anderson TP; Ward PA
    J Clin Invest; 1977 May; 59(5):951-8. PubMed ID: 140184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory dysfunction in leukotaxis.
    Ward PA; Johnson KJ; Kreutzer DL
    Am J Pathol; 1977 Sep; 88(3):701-10. PubMed ID: 142429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin.
    Camussi G; Pawlowski I; Saunders R; Brentjens J; Andres G
    J Lab Clin Med; 1987 Aug; 110(2):196-206. PubMed ID: 2955066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural mediator for PMN emigration in inflammation. VIII. Production of leucoegresin-like chemotactic factor in reversed passive Arthus reactions in rats.
    Nishiura M; Matsumura K; Hayashi H
    Immunology; 1976 Apr; 30(4):521-7. PubMed ID: 131781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of beta 2 integrins of rat neutrophils in complement- and oxygen radical-mediated acute inflammatory injury.
    Mulligan MS; Varani J; Warren JS; Till GO; Smith CW; Anderson DC; Todd RF; Ward PA
    J Immunol; 1992 Mar; 148(6):1847-57. PubMed ID: 1347308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.
    Yeh CG; Marsh HC; Carson GR; Berman L; Concino MF; Scesney SM; Kuestner RE; Skibbens R; Donahue KA; Ip SH
    J Immunol; 1991 Jan; 146(1):250-6. PubMed ID: 1824590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
    Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
    Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
    Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
    J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo responses to inhaled proteins. III. Inhibition of experimental immune complex pneumonitis after suppression of peripheral blood lymphocytes.
    Shenker BJ; Willoughby WF; Hollingdale MR; Mann TN
    J Immunol; 1980 Apr; 124(4):1763-72. PubMed ID: 6245129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific antagonist of platelet-activating factor suppresses oedema formation in an Arthus reaction but not oedema induced by leukocyte chemoattractants in rabbit skin.
    Hellewell PG; Williams TJ
    J Immunol; 1986 Jul; 137(1):302-7. PubMed ID: 2940300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung injury produced by immune complexes of varying composition.
    Scherzer H; Ward PA
    J Immunol; 1978 Sep; 121(3):947-52. PubMed ID: 690444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of IgM rheumatoid factor in experimental immune vasculitis.
    Floyd M; Tesar JT
    Clin Exp Immunol; 1979 Apr; 36(1):165-74. PubMed ID: 157238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathways to inflammation induced by immune complexes: development of the Arthus reaction.
    Crawford JP; Movat HZ; Ranadive NS; Hay JB
    Fed Proc; 1982 Jul; 41(9):2583-7. PubMed ID: 6211371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of anti-inflammatory and other agents on the rat dermal arthus reaction.
    Carter GW; Martin MK; Krause RA; Young PR
    Res Commun Chem Pathol Pharmacol; 1982 Feb; 35(2):189-207. PubMed ID: 6122238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine.
    Mulligan MS; Warren JS; Smith CW; Anderson DC; Yeh CG; Rudolph AR; Ward PA
    J Immunol; 1992 May; 148(10):3086-92. PubMed ID: 1374449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotactic factor inactivator interaction with Gc-globulin (vitamin D-binding protein). A mechanism of modulating the chemotactic activity of C5a.
    Robbins RA; Hamel FG
    J Immunol; 1990 Mar; 144(6):2371-6. PubMed ID: 2313096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of acute and chronic inflammation in tumor-bearing rats.
    Brozna JP; Ward PA
    J Clin Invest; 1979 Jul; 64(1):302-11. PubMed ID: 156198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988.
    Issekutz AC; Szpejda M
    Lab Invest; 1986 Mar; 54(3):275-81. PubMed ID: 3951199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-inflammatory and anti-allergic action of aloperine].
    Zhou CC; Gao HB; Sun XB; Shi HB; Liu W; Yuan HN; Wang ZX
    Zhongguo Yao Li Xue Bao; 1989 Jul; 10(4):360-5. PubMed ID: 2533795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury.
    Gipson TS; Bless NM; Shanley TP; Crouch LD; Bleavins MR; Younkin EM; Sarma V; Gibbs DF; Tefera W; McConnell PC; Mueller WT; Johnson KJ; Ward PA
    J Immunol; 1999 Mar; 162(6):3653-62. PubMed ID: 10092827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.